Phase 1 Dose-Escalation Study of Olaratumab With or Without Chemotherapy in Pediatric Relapsed/Refractory Solid Tumors

Phase 1, open-label trial of olaratumab in Nonhematologic neoplasms, central nervous system tumor and solid neoplasms (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and tolerability of olaratumab alone and in combination with chemotherapy and Maximum tolerated dose / recommended phase 2 dose of olaratumab combinations. Started Jun 2018; status: completed.